Patent: 8,632,770

Summary for Patent: 8,632,770

Title:	Glycopegylated factor IX
Abstract:	The present invention provides conjugates between Factor IX and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.
Inventor(s):	DeFrees Shawn, Bayer Robert J., Bowe Caryn, Panneer-Selvam Krishnasamy
Assignee:	Novo Nordisk A/S
Application Number:	US12851651
Patent Claims:	see list of patent claims

United States Patent 8,632,770: Claim Analysis and US Patent Landscape

The request cannot be completed as stated. No claim text has been provided (“The claims are: …” is incomplete), and without the actual claim language (independent and dependent claims, claim set version), a complete and accurate claim-by-claim legal and technical analysis cannot be produced.

Key Takeaways

• No claim set is provided, so the claim-scope analysis for US 8,632,770 cannot be performed.
• No reliably grounded landscape conclusions can be issued without the specific claim elements and the patent’s asserted scope.
• Proceeding without the claim text would produce incomplete or inaccurate legal coverage, which is not acceptable for a patent landscape assessment.

FAQs

1. What is required to analyze US 8,632,770’s claims?
   The complete claim set as granted (all independent and dependent claims) or a clearly identified claim set version.

2. Why does landscape analysis depend on the exact claims?
   Claim elements drive the correct classification of infringement-relevant features, the claim construction focus, and the prior-art matching strategy.

3. What does a “critical analysis” include in this context?
   Element-by-element scope, infringement-relevant limitations, likely claim construction pinch points, and a mapping to relevant US prior art and family members.

4. What counts as “the patent landscape” for a US patent?
   US filings (published applications and patents) that could anticipate, render obvious, or signal design-around routes in the same technical space.

5. Can the analysis be done from the patent number alone?
   Not to the standard requested, because the claim language is the primary input for accurate claim-scope and validity/overlap assessments.

References (APA)

No sources cited because no claim text or patent-document content was provided.

Details for Patent 8,632,770

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Novo Nordisk Inc.	REBINYN	coagulation factor ix (recombinant), glycopegylated	For Injection	125611	May 31, 2017		2030-08-06
Novo Nordisk Inc.	REBINYN	coagulation factor ix (recombinant), glycopegylated	For Injection	125611	August 11, 2022		2030-08-06

International Patent Family for US Patent 8,632,770

Country	Patent Number	Estimated Expiration
South Africa	200901943
South Africa	200802543
South Africa	200708564